GlassScriptPhysician profile
Joshua Vanderbur
NPI 1417424144
$1,109.28
in general payments reported to CMS, 2019-2025
14 companies · $774 in 2025
The $774 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.63 · 2023: $12.86 · 2024: $309 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $335.42 | 2024-2025 | Epclusa, Yeztugo |
| Viiv Healthcare Company | $321.71 | 2024-2025 | Apretude, Dovato, Cabenuva |
| Theratechnologies INC. | $73.71 | 2025 | Trogarzo, Egrifta |
| Exact Sciences Corporation | $69.27 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $56.26 | 2024 | Spravato |
| Napo Pharmaceuticals INC | $42.79 | 2024-2025 | Mytesi |
| Abbvie INC. | $38.54 | 2024-2025 | |
| Alkermes, INC. | $34.93 | 2025 | Vivitrol |
| Lilly USA, LLC | $31.80 | 2022-2024 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $30.09 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.53 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $19.55 | 2025 | Delstrigo, Pifeltro |
| Glaxosmithkline, LLC. | $18.82 | 2024 | Trelegy Ellipta |
| Organon LLC | $12.86 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Vanderbur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.